Miniproteins Designed for Maximum Potential
Re-Imagining Protein Therapeutics
AI Proteins is on a mission to re-imagine protein-based medicines with ideal therapeutic characteristics. Since our founding in late 2021, our team of experienced protein engineers and drug developers has built a proprietary platform that leverages synthetic biology, robotics and automation, and artificial intelligence. This enables the company to rapidly design, build, and develop highly specific, durable, and inexpensive miniprotein medicines from scratch, with the potential for a variety of administration options.
Our de novo design capabilities give us complete structural control, allowing us to create patentable miniproteins that combine the most desirable characteristics of small molecules and biologics and possess nearly unlimited therapeutic potential. With an initial focus on oncology, inflammation, and metabolic diseases, we have identified novel candidates against a multitude of high value therapeutic targets, and we are currently advancing our own pipeline while also exploring partnerships to realize the full value of our innovations.
Introducing Miniproteins
In this TED talk, AI Proteins co-founder and CSO Chris Bahl introduces miniproteins (also referred to as “constrained peptides”) and describes some of the challenges that we can solve through computational design of these remarkable molecules.
Chris Bahl, MS, PhD
President, Chief Scientific Officer, Co-founder
- Former Head of Protein Design at Institute for Protein Innovation
- Lecturer, Harvard Medical School, Boston Children’s Hospital
- TED Fellow
- Expertise: computational protein design, structural biology, biochemistry, invented de novo design of synthetic miniproteins
James Bowman, PhD
Director of Protein Engineering
Expertise: yeast display, virology, GPCR biochemistry, synthetic miniprotein engineering
María Eugenia Llases MS, PhD
Investigator, Head of Biophysics
Expertise: enzymology, structural biology, biochemistry, protein engineering
Arturo Vera Rodriguez, MS, PhD
Director of Bioprocess Development
Expertise: phage display, protein engineering, biochemistry, structural biology, protein design
Isabelle Moczygemba
Associate Scientist
Expertise: biochemistry, protein production
Mireia Solà Colom, MS, PhD
Investigator, Head of Immunotherapeutics
Expertise: phage display, protein engineering, biochemistry, structural biology
Edson Cárcamo Noriega MS, PhD
Investigator Head of Biochemistry
Expertise: high-throughput protein production, biochemistry, biophysics, venom peptides
Ben Meinen, MS, PhD
Investigator, Head of Protein Design
Expertise: structural biology, biochemistry, protein design, protein folding, yeast display